BAG3 as a target for therapy of heart failure
AssigneeTemple University of the Commonwealth System of Higher Education
InventorsArthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
Life of this patent
Estimating the term…
Abstract
Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
Claims23
A method of treating a human patient suffering from heart failure with reduced ejection fraction, wherein the human patient expresses a decreased level of BCL2-associated athanogene 3 (BAG3) polynucleotide or polypeptide, comprising:
- administering to the human patient a therapeutically effective amount of an isolated BAG3 gene, BAG3 polynucleotide, BAG3 protein, BAG3 polypeptide or an expression vector comprising a BAG3 polynucleotide or cDNA sequence thereof to increase expression or amount of BAG3 polypeptides or proteins in a target cell or tissue in the human patient.
A method of treating a human patient suffering from heart failure with reduced ejection fraction, comprising:
- obtaining a biological sample from a human patient;
- measuring the level of BCL2-associated athanogene 3 (BAG3) polynucleotides, polypeptides in the biological sample and/or detecting a mutation in a BAG3 polynucleotide or polypeptide;
- and,
- administering a BAG3 polynucleotide, expression vector comprising a BAG3 polynucleotide or cDNA sequence thereof, or polypeptide to the human patient if the human patient expresses a decreased level of BAG3 polynucleotide or polypeptide compared to control.
Dependencies are inferred from the claim text.